Ligand Pharmaceuticals impresses with its high-margin licensing business
Ligand already receives 9% of the global net sales for Filspari
Citi analysts see a price potential of around 35%
Reading Time: 2 minutes
Ligand Pharmaceuticals (LGND) is currently at the top of my breakout watchlist among growth stocks. The company adopts an interesting approach as a highly profitable biopharma royalty aggregator. Instead of developing its own drugs, the company is already involved in over 100 programs in the commercial stage or in development. Important technologies for drug development are also offered with Captisol and NITRICIL. Citi analysts have now placed the stock on the "90-Day Catalyst Watch" with a price target of $276 (Buy), as the FDA approval decision...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
